When you choose KANJINTI®
AMGEN HELPS YOU TAKE ON MANY ASPECTS OF PATIENT SUPPORT
KANJINTI® is indicated for the treatment of:3
- HER2-overexpressing breast cancer
- HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
for Herceptin® biosimilarity
The first and only
Herceptin® biosimilar with single-transition study data in the eBC setting
to Herceptin® IV
Available in a
Multi-dose‡ 420 mg vial3,5
The same support you’ve come to expect from AMGEN
Established Q-code: Q5117
*Current as of September 2022.
†NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recognize FDA-approved trastuzumab biosimilars for use in place of trastuzumab (Herceptin®). NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
‡Multi-dose when reconstituted with Bacteriostatic Water for Injection.
HER2 = human epidermal growth factor receptor 2; IV = intravenous; NCCN = National Comprehensive Cancer Network.